Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 26;10(11):2320.
doi: 10.3390/jcm10112320.

Benefits and Risks of Antiviral Treatment during Pregnancy in Patients with Chronic Hepatitis B

Yoon Seok Lee  1 , Soo Min Bang  1 , Young-Sun Lee  1
Affiliations
Review

Benefits and Risks of Antiviral Treatment during Pregnancy in Patients with Chronic Hepatitis B

Yoon Seok Lee et al. J Clin Med. .

Abstract

Hepatitis B virus (HBV) is a main cause of chronic liver disease worldwide and can lead to severe liver diseases. The World Health Organization has planned to eliminate viral hepatitis, including hepatitis caused by HBV and hepatitis C virus, by 2030. As mother-to-child transmission (MTCT) of HBV is a main cause of chronic HBV infection, MTCT prevention is the main target to reduce the risk of chronic HBV infection and eliminate the disease. Recent clinical trials and meta-analyses found that antiviral therapy could prevent MTCT effectively in mothers with ≥200,000 IU/mL of HBV DNA, in combination with serial vaccination and hepatitis B immune globulin administration in infants. Despite the preventive role of antivirals for MTCT of HBV, there are several concerns regarding antiviral therapy with respect to the safety of the mother and fetus during pregnancy. This review summarizes the benefits and risks of antiviral treatment during pregnancy in women with chronic HBV infection.

Keywords: antivirals; hepatitis B virus; mother-to-child transmission; pregnancy; safety; tenofovir.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
HBV screening and prevention of HBV MTCT in pregnant women. MTCT, mother-to-child transmission; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B envelope antigen; HBV DNA, hepatitis B virus DNA; IU, international units; TDF, tenofovir disoproxil fumarate; ALT, alanine aminotransferase; HBIG, hepatitis B immune globulin.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization Global Hepatitis Report. [(accessed on 14 February 2021)];2017 Available online: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/
    1. Stanaway J.D., Flaxman A.D., Naghavi M., Fitzmaurice C., Vos T., Abubakar I., Abu-Raddad L.J., Assadi R., Bhala N., Cowie B., et al. The global burden of viral hepatitis from 1990 to 2013: Findings from the Global Burden of Disease Study 2013. Lancet. 2016;388:1081–1088. doi: 10.1016/S0140-6736(16)30579-7. - DOI - PMC - PubMed
    1. Park S.H., Plank L.D., Suk K.T., Park Y.E., Lee J., Choi J.H., Heo N.Y., Park J., Kim T.O., Moon Y.S., et al. Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017. Clin. Mol. Hepatol. 2020;26:209–215. doi: 10.3350/cmh.2019.0065. - DOI - PMC - PubMed
    1. Cooke G.S., Andrieux-Meyer I., Applegate T.L., Atun R., Burry J.R., Cheinquer H., Dusheiko G., Feld J.J., Gore C., Griswold M.G., et al. Accelerating the elimination of viral hepatitis: A Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol. Hepatol. 2019;4:135–184. doi: 10.1016/s2468-1253(18)30270-x. - DOI - PubMed
    1. Pan C.Q., Zhang J.X. Natural History and Clinical Consequences of Hepatitis B Virus Infection. Int. J. Med. Sci. 2005;2:36–40. doi: 10.7150/ijms.2.36. - DOI - PMC - PubMed